Amoxicillin high-dose dual therapy for Helicobacter pylori primary eradication: Proton pump inhibitor and potassium-competitive acid blocker, which’s better?

doi:10.3748/wjg.v31.i13.100863

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 31, Issue 13

This Article

(127)

(122)

(0)

(20)

(1)

(7780)

(12)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Randomized Controlled Trial

World J Gastroenterol. Apr 7, 2025; 31(13): 100863
Published online Apr 7, 2025. doi: 10.3748/wjg.v31.i13.100863

Table 6 Univariate analysis of factors related to eradication rates, n (%)

Variables	14d-EA group and 14d-B-quadruple group (n = 353)		14d-VA group and 14d-VAC group (n = 325)
Variables	Eradication rate (success/total)	P value	Eradication rate (success/total)	P value
Gender
Male	151/158 (95.57)	0.879	141/149 (94.63)	0.902
Female	187/195 (95.90)		166/176 (94.32)
Age
≤ 60 years	319/333 (95.80)	0.591	278/295 (94.24)	0.892
> 60 years	19/20 (95.00)		29/30 (96.67)
Fixed occupation
Yes	209/219 (95.43)	0.706	184/194 (94.85)	0.713
No	129/134 (96.27)		123/131 (93.89)
BMI, kg/m²
< 22	116/123 (94.31)	0.271	128/136 (94.12)	0.092
22-25	140/147 (95.24)		116/119 (97.48)
> 25	82/83 (98.80)		63/70 (90.00)
BSA, m²
< 1.65	171/181 (94.48)	0.223	174/184 (94.57)	0.926
≥ 1.65	167/172 (97.09)		133/141 (94.33)
Education status
Primary	28/30 (93.33)	0.280	25/26 (96.15)	0.954
Junior high school	45/47 (95.74)		38/40 (95.00)
High school	54/58 (93.10)		58/61 (95.08)
College	154/161 (95.65)		140/148 (94.59)
Above university	57/57 (100.00)		46/50 (92.00)
Place of residence
Urban area	278/285 (97.54)	0.001^a	252/263 (95.82)	0.004^a
Suburban area	36/43 (83.72)		31/38 (81.58)
Rural area	24/25 (96.00)		24/24 (100.00)
Smoking
Yes	85/89 (95.51)	1.000	75/80 (93.75)	0.969
No	253/264 (95.83)		232/245 (94.69)
Drinking
Frequent	21/22 (95.45)	0.822	18/19 (94.74)	0.768
Occasional	89/92 (96.74)		81/87 (93.10)
None	228/239 (95.40)		208/219 (94.98)
Past medical history
Yes	59/61 (96.72)	0.949	53/55 (96.36)	0.724
No	279/292 (95.55)		254/270 (94.07)
Family infection of H. pylori
Yes	108/112 (96.43)	0.895	86/93 (92.47)	0.449
No	126/132 (95.45)		129/134 (96.27)
Undetected	104/109 (95.41)		92/98 (93.88)
Digestive symptoms
Yes	256/268 (95.52)	0.945	246/259 (94.98)	0.611
No	82/85 (96.47)		61/66 (92.42)
Endoscopy diagnosis
Yes	230/242 (95.04)	0.489	205/219 (93.61)	0.333
No	108/111 (97.30)		102/106 (96.23)
Atrophic gastritis
Yes	62/65 (95.38)	1.000	59/63 (93.65)	0.995
No	276/288 (95.83)		248/262 (94.66)
History of antibiotics use in 2 years
Yes	170/183 (92.90)	0.006^a	150/165 (90.91)	0.004^a
No	168/170 (98.82)		157/160 (98.13)
Relief of symptoms
No symptoms	82/85 (96.47)	0.418	61/66 (92.42)	0.318
Remission	173/184 (94.02)		161/168 (95.83)
Symptoms disappeared	69/70 (98.57)		71/75 (94.67)
No	14/14 (100.00)		14/16 (87.50)
Adverse events
Yes	21/21 (100.00)	1.000	31/33 (93.94)	1.000
No	317/332 (95.48)		276/292 (94.52)
Compliance
Good	337/350 (96.29)	0.005^a	299/314 (95.22)	0.018^a
Poor	1/3 (33.33)		8/11 (72.73)

^aP < 0.05.

BMI: Body mass index; BSA: Body surface area; EA: Esomeprazole-amoxicillin; B-quadruple: Esomeprazole-amoxicillin-clarithromycin-bismuth; VA: Vonoprazan-amoxicillin; VAC: Vonoprazan-amoxicillin-clarithromycin.

Full Size Table

Citation: Yang XE, Zhang SJ, Liu Y, Yao SY, Zhang SX, Liu XM, Liang LX, Wang F. Amoxicillin high-dose dual therapy for Helicobacter pylori primary eradication: Proton pump inhibitor and potassium-competitive acid blocker, which’s better? World J Gastroenterol 2025; 31(13): 100863
URL: https://www.wjgnet.com/1007-9327/full/v31/i13/100863.htm
DOI: https://dx.doi.org/10.3748/wjg.v31.i13.100863

Yang XE, Zhang SJ, Liu Y, Yao SY, Zhang SX, Liu XM, Liang LX, Wang F. Amoxicillin high-dose dual therapy for Helicobacter pylori primary eradication: Proton pump inhibitor and potassium-competitive acid blocker, which’s better? World J Gastroenterol 2025; 31(13): 100863 [PMID: 40248055 DOI: 10.3748/wjg.v31.i13.100863]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.